Almiral Use In Pregnancy & Lactation

Pregnancy: There are insufficient data on the use of diclofenac in pregnant women. Therefore, Almiral should not be used during the first two trimesters of pregnancy unless the expected benefits to the mother outweigh the risks to the fetus. Use of NSAIDs at about 20 weeks gestation or later in pregnancy may cause foetal renal dysfunction leading to oligohydramnios and in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. As with other NSAIDs, use of diclofenac during the third trimester of pregnancy is contraindicated owing to the possibility of uterine inertia and/or premature closure of the ductus arteriosus (see CONTRAINDICATIONS and PHARMACOLOGY: TOXICOLOGY: NON-CLINICAL SAFETY DATA under ACTIONS).
Breast-feeding: Diclofenac passes into the breast milk in small amounts. Therefore, Almiral should not be administered during breast feeding in order to avoid undesirable effects in the infant.
Fertility: The use of Almiral may impair female fertility and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Almiral should be considered.